Pitavastatin

Medicure Announces Settlement of Holdback Dispute from Apicore Sale

Retrieved on: 
Thursday, December 5, 2019
Chemical compounds, Organic compounds, Piperidines, Sulfonamides, Tirofiban, Pitavastatin, Pharmaceutical industry

WINNIPEG, Dec. 5, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.

Key Points: 
  • WINNIPEG, Dec. 5, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.
  • A settlement agreement was reached under which Medicure will receive a net payment of US$5.1 million in relation to the holdback.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • The present focus of the Company is the marketing and distribution of AGGRASTAT(tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com .

Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)

Retrieved on: 
Thursday, June 20, 2019
Health, Cardiology, Clinical trials, Genetics, Pharmaceutical, FDA, General Health, Organic compounds, Chemical compounds, Eli Lilly and Company, Beta hydroxy acids, Carboxylic acids, Diols, Statins, Pitavastatin, Hypercholesterolemia, Cholesterol, Iduronidase, Health, Cardiology, Clinical trials, Genetics, Pharmaceutical, FDA, General Health, Chemical compounds, Organic compounds, Health, Cyclopropanes, Diols, Pitavastatin, Quinolines, Statins, Hypercholesterolemia, Cholesterol, Food and Drug Administration

The approval was granted in conjunction with fulfillment of FDAs Written Request to obtain pediatric information on pitavastatin and provides a 6-month pediatric exclusivity with regard to the U.S. patent protection for LIVALO.

Key Points: 
  • The approval was granted in conjunction with fulfillment of FDAs Written Request to obtain pediatric information on pitavastatin and provides a 6-month pediatric exclusivity with regard to the U.S. patent protection for LIVALO.
  • The pediatric label indication for LIVALO is supported by a 12-week, double-blind, placebo-controlled trial in 82 pediatric patients 8 to 16 years of age with HeFH, and a 52-week open-label trial in 85 pediatric patients with HeFH.
  • High cholesterol is defined as total cholesterol 240 mg/dL based on guidelines from the National Institutes of Health (NIH).
  • Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, AL, is focused primarily in the area of cardiometabolic diseases.